First-Line Treatment for Interstitial Pneumonia
The first-line treatment for interstitial pneumonia depends critically on the underlying etiology: for systemic autoimmune rheumatic disease-associated ILD (SARD-ILD), mycophenolate is the preferred immunosuppressive agent; for idiopathic pulmonary fibrosis (IPF), antifibrotic therapy with nintedanib or pirfenidone is indicated; and for immune checkpoint inhibitor-related pneumonitis, corticosteroids are the mainstay of treatment.
Treatment Algorithm Based on Etiology
SARD-Associated Interstitial Lung Disease
Mycophenolate is conditionally recommended as the preferred first-line therapy across all SARD-ILD subtypes 1. The 2023 ACR/CHEST guidelines establish a clear hierarchy where mycophenolate ranks above other immunosuppressive options including azathioprine, rituximab, and cyclophosphamide 1.
Key disease-specific considerations:
Systemic Sclerosis-ILD (SSc-ILD): Strongly avoid glucocorticoids as first-line therapy due to increased risk of scleroderma renal crisis, particularly at doses >15 mg/day prednisone equivalent 1. Mycophenolate remains preferred, with tocilizumab and nintedanib as conditional options 1.
Rheumatoid Arthritis-ILD (RA-ILD): Mycophenolate is preferred over other immunosuppressants 1, 2. The 2026 Pan American League guidelines conditionally recommend methotrexate, rituximab, abatacept, or targeted synthetic DMARDs 2. Nintedanib shows no consensus as first-line but is conditionally recommended for progressive disease 1.
Inflammatory Myositis-ILD (IIM-ILD): Mycophenolate remains preferred, but JAK inhibitors and calcineurin inhibitors are conditionally recommended as first-line options specifically for this subtype 1.
Other SARD-ILD (Sjögren's, MCTD): Short-term glucocorticoids (≤3 months) may be conditionally recommended alongside mycophenolate, except in SSc-ILD 1.
Agents to avoid as first-line: Leflunomide, methotrexate, TNF inhibitors, and abatacept are conditionally recommended against 1.
Idiopathic Pulmonary Fibrosis
Antifibrotic therapy with either nintedanib or pirfenidone is first-line treatment for IPF 3. These agents slow annual FVC decline by approximately 44-57% 3. The choice between the two depends on tolerability profile and cost considerations, as efficacy is comparable.
Critical distinction: Immunosuppression is contraindicated in IPF following the PANTHER study results 4. This represents a fundamental difference from SARD-ILD management.
Immune Checkpoint Inhibitor-Related Pneumonitis
Corticosteroids are the first-line treatment for immune-related pneumonitis 5, 6, 7:
- Grade 1: Withhold ICI, monitor every 2-3 days, consider rechallenge after resolution
- Grade 2: 1 mg/kg/day prednisolone (or equivalent), taper over 4-6 weeks 5
- Grade 3: 1-2 mg/kg/day methylprednisolone IV, taper over 6-8 weeks 5
- Grade 4: High-dose IV corticosteroids plus consideration of additional immunosuppression (tocilizumab 8 mg/kg, infliximab 5 mg/kg, IVIG 2 g/kg, or mycophenolate mofetil 1 g twice daily) if no improvement within 72 hours 5, 6
Permanent ICI discontinuation is required for grade ≥3 pneumonitis 6.
Progressive Disease Management
When first-line therapy fails to control disease progression:
SARD-ILD: Continue mycophenolate and add nintedanib, or switch to rituximab or cyclophosphamide 1. For RA-ILD specifically, adding pirfenidone is conditionally recommended 1, 2.
Rapidly Progressive ILD: Requires IV glucocorticoids (except uncertain in SSc-ILD) plus combination therapy with 1-2 additional agents: rituximab, cyclophosphamide, IVIG, mycophenolate, or JAK inhibitors (particularly for anti-MDA-5 positive patients) 1. Early lung transplant referral should be considered 1.
Critical Pitfalls to Avoid
- Do not use immunosuppression for IPF - this worsens outcomes based on PANTHER trial data 4
- Do not use glucocorticoids as first-line in SSc-ILD - strong recommendation against due to renal crisis risk 1
- Do not rapidly taper corticosteroids in immune-related pneumonitis - minimum 4-6 week taper required to prevent recrudescence 6
- Do not use upfront combination antifibrotic plus immunosuppression - conditionally recommended against in SARD-ILD 1
Monitoring and Adjunctive Therapy
Regardless of etiology, structured exercise therapy improves 6-minute walk distance and quality of life 3. Oxygen therapy is indicated for patients who desaturate below 88% on 6-minute walk test 3. Lung transplant referral should occur early in progressive disease, as post-transplant median survival (5.2-6.7 years) exceeds advanced ILD survival (<2 years) 3.